DaVita Inc
DVA: XNYS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|^@ | LOCK|lmm^y | LOCK|wH#Y!s< |
DaVita Earnings: Higher Revenue Per Treatment Helps Boost 2024 Outlook and Fair Value
Narrow-moat DaVita turned in solid second-quarter results, and management bumped up its bottom-line expectations slightly. To reflect those mildly higher near-term expectations and recent cash flows, we are raising our fair value estimate on DaVita to $134 per share from $122.
